CatalystMarker
← board

ELTX

Elicio Therapeuticsdistress 5/10 · elevated risk
$3.16+1%today-79% from 52w high
elicio.com33 employeesBoston, MABiotechnology
Lead: Pancreatic Ductal Adenocarcinoma · est. market ~$5B (approx, global)
Revenue
pre-revenue
Liquidity
$15M
Runway
0.4 yrs
Shares 1y
+17%

Price & events

-60.5% over 6M
$2.76$8.81$14.85Jan 26Apr 26Jul 2651.1Mdilution: 424B5 offering (2026-07-02)dilution: EFFECT shelf_effective (2026-03-16)dilution: 424B5 offering (2026-03-16)dilution: S-3/A shelf_registration (2026-03-12)dilution: S-3/A shelf_registration (2026-03-02)dilution: S-3 shelf_registration (2026-02-27)financing: 8-K material_agreement (2026-07-02)financing: 8-K material_agreement (2026-03-16)rating: Jones Trading: Buy → Hold (2026-06-16)rating: HC Wainwright & Co.: Buy (2026-06-15)rating: B. Riley Securities: Buy (2026-06-10)rating: HC Wainwright & Co.: Buy (2026-05-28)rating: Ladenburg Thalmann: Buy (2026-04-15)rating: HC Wainwright & Co.: Buy (2026-03-13)rating: Rodman & Renshaw: Buy (2026-03-10)
CatalystRating changeDilutionFinancingdashed = today
+1.3%
1D
-1.2%
1W
-23.1%
1M
-73.3%
3M
-61.0%
6M
-67.8%
1Y
-32.6%
2Y
-97.1%
5Y
-98.1%
All

Overview

Market Cap
$60.31M
Enterprise Value
$54.84M
Volume
22.36K
52 Week Range
$2.76 – $14.85
Total Shares
19.09M
Float Shares
10.77M
Short %
13.13%
% Held by Insiders
24.68%
% Held by Institutions
16.85%
RVOL
0.01x
Beta
1.78

Pipeline stages · 1 programs

ELI-002 7P
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2026-11

Pipeline · 1 trials · 1 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
2026-11
Estimated 50%
readout ~2026-12-16
Phase 1/2ELI-002 7PPancreatic Ductal Adenocarcinoma, Colorectal Cancer, KRAS G12D, KRAS G12R, KRAS G12V, KRAS G12A, KRAS G12C, KRAS G12S, KRAS G13D, NRAS G12D, NRAS G12R, NRAS G12V, NRAS G12C, NRAS G12S—active not recruiting

Catalyst news & presentations · 3

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 19,086,081 · 2 offerings/1y · 0 PIPEs
  • 2026-07-028-Kmaterial_agreement
  • 2026-07-02424B5offering
  • 2026-03-168-Kmaterial_agreement
  • 2026-03-16424B5offering
  • 2026-03-16EFFECTshelf_effective
  • 2026-03-12S-3/Ashelf_registration
  • 2026-03-02S-3/Ashelf_registration
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

strong buy · target $20 (+533% upside) · 3 analysts
  • 2026-06-16Jones TradingBuy → Hold
  • 2026-06-15HC Wainwright & Co.Buy
  • 2026-06-10B. Riley SecuritiesBuy
  • 2026-05-28HC Wainwright & Co.Buy
  • 2026-04-15Ladenburg ThalmannBuy
  • 2026-03-13HC Wainwright & Co.Buy

Competitors — Pancreatic Ductal Adenocarcinoma

  • LLYELI LILLY & Co$1094.4B · D3
  • NVSEFNOVARTIS AG$292.0B · D3
  • PFEPFIZER INC$142.2B · D3
  • RVMDRevolution Medicines, Inc.$40.3B · D1
  • VSTMVerastem, Inc.$515M · D5
  • CELG-RIBRISTOL MYERS SQUIBB CO$241M · D2
  • ACTUACTUATE THERAPEUTICS, INC.$31M · D8
  • LSTALISATA THERAPEUTICS, INC.$20M · D4
  • TOVXTheriva Biologics, Inc.$10M · D8
  • AZNASTRAZENECA PLC— · D3

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.